Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Identifying Drugs that Suppress Childhood Liver Diseases

EF 2020-21

Résumé
Progressive Familial Intrahepatic Cholestasis is a rare childhood disease where dysfunctional proteins in liver cells cannot support bile flow from the liver to the duodenum. Consequently, a build-up of bile acids occurs within the liver, leading to nutrition deficiencies, and other serious adverse effects including biliary stones, ductal fibrosis and liver scarring. Mild cases are treated with therapeutic agents; however, the majority of patients do not respond, and liver transplants are almost always required. Our goal is to discover a superior pharmacologic treatment resulting in restoration of bile composition facilitating proper liver function and nutrient processing. Work in our collaborator's lab has established 14 FDA-approved drugs that successfully reverse this disease in a nematode model. We propose to test these drugs in vitro using a cell culture model expressing human proteins and in a mouse model of the disease. We hypothesize that these drugs will restore the composition of bile by altering phospholipid composition, restore bile flow and alleviate the disease phenotype. To model the disease in cells, we will over-express the proteins required for bile formation and determine whether the 14 drugs impact the integrity of the plasma membrane. Furthermore, transgenic mice with dysfunctional transport proteins required to make bile will be treated with the drugs, and blood and bile will be collected to assess the effects of the drugs on the composition of bile when compared to vehicle treatment. This project aims to determine whether these drugs can inhibit dysfunctional transport proteins, thereby suppressing the cholestatic phenotype of the disease. Although this disease is rare, the development of an effective therapeutic will be life-altering.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
449531
Name
Cash Sarah B
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying Drugs that Suppress Childhood Liver Diseases
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bile Acid Secretion And Transport; Bile Salt Export Protein; Progressive Familial Intrahepatic Cholestasis
Abstract
Progressive Familial Intrahepatic Cholestasis is a rare childhood disease where dysfunctional proteins in liver cells cannot support bile flow from the liver to the duodenum. Consequently, a build-up of bile acids occurs within the liver, leading to nutrition deficiencies, and other serious adverse effects including biliary stones, ductal fibrosis and liver scarring. Mild cases are treated with therapeutic agents; however, the majority of patients do not respond, and liver transplants are almost always required. Our goal is to discover a superior pharmacologic treatment resulting in restoration of bile composition facilitating proper liver function and nutrient processing. Work in our collaborator's lab has established 14 FDA-approved drugs that successfully reverse this disease in a nematode model. We propose to test these drugs in vitro using a cell culture model expressing human proteins and in a mouse model of the disease. We hypothesize that these drugs will restore the composition of bile by altering phospholipid composition, restore bile flow and alleviate the disease phenotype. To model the disease in cells, we will over-express the proteins required for bile formation and determine whether the 14 drugs impact the integrity of the plasma membrane. Furthermore, transgenic mice with dysfunctional transport proteins required to make bile will be treated with the drugs, and blood and bile will be collected to assess the effects of the drugs on the composition of bile when compared to vehicle treatment. This project aims to determine whether these drugs can inhibit dysfunctional transport proteins, thereby suppressing the cholestatic phenotype of the disease. Although this disease is rare, the development of an effective therapeutic will be life-altering.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cash, Sarah B
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~